A 58-year-old Malay female with underlying diabetes mellitus, presented with chronic skin lesions, associated with weight loss and anemia. There were erosive, scaling skin lesions over the extremities, gluteal region and perioral area. Skin biopsy histopathological examination revealed Necrolytic Migratory Erythema (NME). A CT scan of the abdomen revealed a pancreatic neck and body tumor with possible liver metastases. She was successfully treated with subcutaneous somatostatin and underwent distal pancreatectomy with wedge resection of liver nodule.
INTRODUCTION
Neuroendocrine tumors (NET) are also known as Gastroentero-pancreatic neuroendocrine tumors (GEP-NETs). They arise from cells of diffuse neuroendocrine systems such as enterochromaffin cells which possess secretory granules and release neurohormones. 1 Pancreatic NETs present with typical syndromes which include insulinoma, gastrinoma, glucagonoma, VIPomas, somatostatinomas and non-syndromic pancreatic NETs. 1 A glucagonoma is a rare pancreatic NET with an estimated incidence of 1 in 20 million people per year. 2 Glucagonomas arises from islet alpha cells commonly at the tail of the pancreas. 3 The World Health Organization (WHO) classification of endocrine tumors 4 recommended that glucagonomas should be differentiated from nonfunctioning pancreatic alpha cell tumors and thus, is defined by its clinical syndromes. Glucagonomas may arise sporadically or in patients with Multiple Endocrine Neoplasia (MEN) type 1 5 which is rare (<3%). As depicted in our patient's case, patients with glucagonoma usually presents in the middle age group with median age of 53.5 years. 6 
CASE
A 58-year-old Malay female, with a background history of diabetes mellitus and hypertension for 2 years, presented with chronic, on-and-off skin lesions over the lower limbs and abdomen for the past 2 years. It usually starts with a skin blister which later ruptures and ulcerates with a necrotic patch. Other symptoms included lethargy and profound weight loss (20 kg in a year). The patient also had a history of anemia, abdominal pain and dyspepsia. Upper gastrointestinal endoscopy done previously only revealed mild gastritis. There was no history of chronic diarrhea, anorexia, history of mood changes or any history to suggest venous thrombosis.
Physical examination revealed a pale, cachectic lady with erythematous, erosive scaling with crusted skin patches over the upper and lower extremities, gluteal region and perioral region (Figure 1a The patient was referred to the dermatology service and skin biopsy was done which revealed mild acanthosis with marked spongiosis. There was hyperkeratosis and parakeratosis as well as plasma, neutrophils and bacterial colonies on the keratin layers. The dermis shows perivascular and interstitial infiltration by lymphocytes, neutrophils and eosinophils. This findings are suggestive of infection and features are compatible with NME. Subsequently, CT scan of the abdomen was done which revealed a pancreatic neck and body tumor most likely representing glucagonoma (5.5 x 2 x 3 cm) with possible liver metastases. (Figure 2a-c) . Further investigations revealed raised serum Chromogranin A >770 ng/ml and serum glucagon of 1068 pg/ml (50-150).
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DISCUSSION
Glucagonoma Syndromes (GS) are paraneoplastic syndromes consisting of a clinical triad which includes glucagon-secreting pancreatic tumor, diabetes mellitus (DM) and NME. 7 Stacpoole suggested a set of diagnostic criteria for glucagonoma in which all criteria should be fulfilled. 8 The diagnostic criteria consist of demonstration of the tumor by direct visualisation or radiographically, proof that the tumor shows a preponderance of glucagoncontaining cells on appropriate staining and/or proof of increased tissue levels of immunoreactive glucagon; elevation of basal circulating immunoreactive glucagon; and at least one of the following coincidental findings; (a) skin rash, (b) glucose intolerance, or (c) hypoaminoacidemia. Other clinical syndromes associated with glucagonoma are stomatitis, anaemia, 9 venous thromboembolism 10 neuropsychiatric disturbances (most often depression and/or psychosis), 11 diarrhoea and, rarely, dilated cardiomyopathy. GS can be further classified into 3 clinical types i.e., glucagonoma with skin syndrome (NME), glucagonoma with mild diabetes and glucagonoma with multiple syndromes. 12 Our patient fulfilled all the diagnostic criteria for glucagonoma and belongs to the last group with presence of diabetes and NME. NME is present in almost 70% of patients. 13,14 NME is characterised by irregular annular eruptions (central healing area) with serpiginous advancing borders, erosion, and crusting, resulting in a scalded appearance. 15 It is suggestive of glucagonoma but is not pathognomonic for the syndrome. NME was also reported to be found in other disorders such as hepatic dysfunction and cirrhosis, 16 jejunal and rectal adenocarcinoma, villous atrophy of the small intestines and myelodysplastic syndromes. 6 The skin eruption usually involves the inguinal canal, perineum, buttocks and lower extremities. 7 It is characterized by cyclical pattern of spontaneous remission and exacerbation. 7 The underlying cause for NME skin changes is still unclear. Increased glucagon perÊ se does not cause NME since it was also reported in other disorders not related to high glucagon level as mentioned above. However, normalisation of glucagon level by means of surgery or somatostatin analogues invariably results in rapid resolution of NME. 15 Hyperglucagonemia probably provokes the metabolic deficiency of zinc, essential fatty acids and amino acids and has been considered as a possible cause of NME. However, not all patients with NME present with these metabolic changes, and not all patients with NME and metabolic deficiency achieve complete resolution of the skin lesion with supplementation. 17 Early recognition of NME is essential as it will prevent catabolic clinical features and reduce the risk of metastasis. 18 Impaired fasting glycaemia or diabetes mellitus is present in 80% of patients with GS. 19 The tumor secretes high levels of glucagon which in turn promotes glycogenolysis, gluconeogenesis, ketogenesis and lipidioresis by activating phosphorylase in the liver, stimulating secretion of insulin and inhibiting external secretion of the pancreas, thus resulting in hyperglycaemia. 18 Hyperglucagonemia reduces plasma amino acid concentration and stimulates amino acid catabolism. 18 The diagnosis of glucagonoma in this case was confirmed by elevated plasma glucagon levels in keeping with similar findings in all patients in a case series in which the glucagon level ranged from 200 to >10,000 pmol. 6 Plasma glucagon levels are usually elevated 10 to 20-fold in patients with glucagonoma (normal <50 pg/mL). Concentrations above 1000 pg/mL are virtually diagnostic of glucagonoma. 20 Chromogranin A (Cg A) level was elevated in our case and in half of subjects in the case series. 6 Cg A is a NETs biomarker and is expressed in almost 90% of NETs independent of its site of origin. 21 It can aid in the diagnosis of NETs and can also be used as prognosis and as a biomarker to monitor disease progression. 21 Another biochemical result noted was anemia. Plurihormonal secretion of the tumor (serum glucagon, gastrin and chromogranin A) confers a guarded prognosis with short survival possibly due to the less-differentiated nature of the plurihormonal subtype. 6 Somatostatin receptor scan (SRS) was positive in most of the patients in a case series. 6 It is frequently used as a complementary method to conventional imaging like CT scan and MRI for supervision of somatostatin expression and dissemination of tumor metastases. 22, 23 As illustrated in our patient case, the pancreatic tumor was readily visualised by CT scan imaging and the size was comparable with the average size of 6 cm reported in a case series. 24 However, the position of the tumor at the neck and body of the pancreas was not classic for glucagonoma, which is more commonly found at the tail of the pancreas (45-75%). 12 CT scan is usually the initial non-invasive radiographic test. Other imaging techniques that can be used to detect the tumor are abdominal ultrasound, MRI and selective visceral angiography. 7 Selective angiography of the celiac and superior mesenteric 15 arteries is the gold standard in the diagnosis and localisation of glucagonoma as this tumor shows significant hypervascularity. 7 In addition, this technique is able to demonstrate hepatic metastases even in a patient with a negative liver scan. 7 The role of pancreatic venous sampling for glucagon levels in the diagnosis of small 
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CONCLUSION
• Long-term -history and physical examination with tumor markers every 6 to 12 months for years 1 to 3, and as clinically indicated thereafter. Imaging studies are recommended only as clinically indicated.
Glucagonoma is a rare NET with a subtle, variable presentation leading to late diagnosis. Therefore increased awareness and recognition of Glucagonoma Syndrome is vital in order for early diagnosis before development of metastases.
